A mixed methods study to assess the feasibility of a randomized controlled trial of invasive urodynamic testing versus clinical assessment and non-invasive tests prior to surgery for stress urinary incontinence in women: the INVESTIGATE-I study by Hilton P et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
Hilton P, Armstrong N, Brennand C, Howel D, Shen J, Bryant A, Tincello DG, 
Lucas MG, Buckley BS, Chapple CR, Homer T, Vale L, McColl E. 
A mixed methods study to assess the feasibility of a randomized controlled 
trial of invasive urodynamic testing versus clinical assessment and non-
invasive tests prior to surgery for stress urinary incontinence in women: the 
INVESTIGATE-I study. 
Trials 2015, 16, 400 
Copyright: 
© 2015 Hilton et al. Open Access This article is distributed under the terms of the Creative Commons 
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit 
to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver 
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this 
article, unless otherwise stated. 
 
DOI link to article: 
http://dx.doi.org/10.1186/s13063-015-0928-2 
 
Date deposited:   
16/12/2015 
  
A mixed methods study to assess the feasibility of
a randomised controlled trial of invasive
urodynamic testing versus clinical assessment and
non-invasive tests prior to surgery for stress
urinary incontinence in women: the INVESTIGATE-I
study
Hilton et al.
Hilton et al. Trials  (2015) 16:400 
DOI 10.1186/s13063-015-0928-2
RESEARCH Open Access
A mixed methods study to assess the
feasibility of a randomised controlled trial of
invasive urodynamic testing versus clinical
assessment and non-invasive tests prior to
surgery for stress urinary incontinence in
women: the INVESTIGATE-I study
Paul Hilton1,8*, Natalie Armstrong2, Catherine Brennand3, Denise Howel4, Jing Shen4, Andrew Bryant4,
Douglas G. Tincello2, Malcolm G. Lucas5, Brian S. Buckley6, Christopher R. Chapple7, Tara Homer4, Luke Vale4,
Elaine McColl3,4 and on behalf of the INVESTIGATE studies group
Abstract
Background: The position of invasive urodynamic testing (IUT) in diagnostic pathways for urinary incontinence is
unclear, and systematic reviews have called for further trials evaluating clinical utility. The objective of this study was
to inform the decision whether to proceed to a definitive randomised trial of IUT compared to clinical assessment
with non-invasive tests, prior to surgery in women with stress urinary incontinence (SUI) or stress-predominant mixed
urinary incontinence (MUI).
Methods: A mixed methods study comprising a pragmatic multicentre randomised pilot trial, a qualitative face-to face
interview study with patients eligible for the trial, an exploratory economic evaluation including value of information
study, a survey of clinicians’ views about IUT, and qualitative telephone interviews with purposively sampled survey
respondents. Only the first and second of these elements are reported here.
Trial participants were randomised to either clinical assessment with non-invasive tests (control arm) or clinical
assessment with non-invasive tests plus IUT (intervention arm).
The main outcome measures of these feasibility studies were confirmation that units can identify and recruit eligible
women, acceptability of investigation strategies and data collection tools, and acquisition of outcome data to determine
the sample size for a definitive trial. The primary outcome proposed for a definitive trial was ICIQ-FLUTS (total score) 6
months after surgery or the start of nonsurgical treatment.
Results: Of 284 eligible women, 222 (78 %) were recruited, 165/219 (75 %) returned questionnaires at baseline, and 125/
200 returned them (63 %) at follow-up. Most women underwent surgery; management plans were changed in 19 (19 %)
participants following IUT.
Participants interviewed were positive about the trial and the associated documentation.
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Conclusions: All elements of a definitive trial were rehearsed. Such a trial would require between 232 and 922
participants, depending on the target difference in the primary outcome. We identified possible modifications to
our protocol for application in a definitive trial including clarity over inclusion/exclusions, screening processes, reduction in
secondary outcomes, and modification to patient questionnaire booklets and bladder diaries. A definitive trial of IUT
versus clinical assessment prior to surgery for SUI or stress predominant MUI is feasible and remains relevant.
Trial registration: Current Controlled Trials: ISRCTN 71327395, registered 7 June 2010.
Keywords: feasibility studies, pilot studies, interview studies, randomised controlled trial, stress urinary incontinence,
urodynamics
Background
Urinary incontinence (UI), whilst rarely life-threatening,
may seriously influence the physical, psychological and
social wellbeing of affected individuals [1–4]. The impact
on families and carers may be profound and the re-
source implications for health services considerable [5].
Prevalence figures for UI range from 5 % to 69 % in
women 15 years and older, with most studies showing
prevalence in the range 25 to 45 % [6]; stress (SUI) or
mixed urinary incontinence (MUI) account for 65–85 %
of cases [7].
Several methods are used in the assessment of UI
to guide management decisions; some of these are
non-invasive (for example, urine culture, bladder diar-
ies or frequency volume charts, urine flow rate and
post-void residual volume measurement), and some
are invasive (that is, require catheterisation). Cysto-
metry, the most commonly used invasive urodynamic
test (IUT), looks at the pressure/volume relations
during bladder filling, storage and emptying, with a
view to defining a functional diagnosis as distinct
from a purely symptomatic one.
The current position of IUT in the diagnostic path-
way is not agreed upon, and practices vary consider-
ably; in a UK survey in 2002, only half of the units
surveyed had a guideline on indications for the tests,
and 85 % carried out cystometry in all women with
incontinence [8]. Current guidance from the National
Institute for Health and Care Excellence (NICE), how-
ever, suggests that cystometry is not required prior to
conservative treatments for UI, nor prior to surgery
where the diagnosis of SUI is clear on clinical
grounds (that is, where there are no symptoms of
overactive bladder (OAB) or voiding dysfunction, no
anterior compartment prolapse, and no previous sur-
gery for SUI) [9–12].
Changes in available operative techniques, and in
particular the introduction of less invasive approaches
such as mid-urethral tapes, have resulted in dramatic
alterations to surgical practice in recent years [13].
Hospital Episode Statistics (HES) demonstrated a 50 %
increase in surgery for SUI in the 10 years following the
introduction of mid-urethral tapes in 1997, with numbers
apparently plateauing at 11,000 to 13,000 procedures annu-
ally in England between 2006 and 2007 and between 2012
and 2013 [14]. Were the NICE guidance to be applied, the
annual savings from more rational use of IUT prior to
surgery for SUI, based on 2012/13 national tariff costs
(£403 per procedure for Healthcare Resource Group
LB42Z) [15] and HES activity data [14], would be approxi-
mately £3.3 million. There would also be an additional ‘op-
portunity cost’ savings from the alternative use of staff and
equipment currently devoted to IUT. On the other hand, it
must be recognised that there are increasing concerns
about the long-term safety of vaginal mesh implants [16],
which might argue more in favour of increasing use of in-
vestigation to ensure the most rational use of surgery.
Two trials looking at the clinical utility of urodynam-
ics in women with SUI have been published recently,
both using a non-inferiority design. The VUSIS-1 trial
from the Netherlands was terminated prematurely due
to slow recruitment after achieving only 23 % (59/260)
of its planned accrual [17]. In view of the recruitment
difficulties with VUSIS-1, the group proceeded to a fur-
ther study of alternative design, (VUSIS-2) in which all
women underwent IUT, and only those with discordant
clinical and urodynamic findings were randomised be-
tween surgical treatment (as dictated by their clinical
assessment) and individualized treatment (dictated by
the combination of clinical and urodynamic results);
neither participants nor healthcare professionals in-
volved were blinded to the urodynamic results in either
group [18].
The ValUE trial from the USA defined a non-inferiority
margin of 11 % [19]; this is equivalent to a standardised
difference of <0.8, which may be considered high in statis-
tical terms. [20] A difference in outcome between groups of
11 % may also be considered important in clinical terms,
potentially influencing the decisions of both clinicians and
patients. Notwithstanding these limitations, both studies
reported that, in women with uncomplicated SUI, treat-
ment (usually an immediate mid-urethral sling operation)
based on basic clinical evaluation is not inferior to individu-
ally tailored treatment based on urodynamic findings.
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Each of these studies was published during the period of
recruitment and follow-up in INVESTIGATE-I [17, 19, 21].
How much they have already influenced clinical opinion
and practice, or will do so in the future, is unclear, al-
though a ‘point-counterpoint’ debate published after these
studies makes it clear that there is still a question to be an-
swered [22, 23]. The most recent update of the Cochrane
review of urodynamics for the management of urinary in-
continence in children and adults included the data from
these two trials, yet continued to emphasise the need for
larger definitive trials, in which people are randomly allo-
cated to management according to urodynamic findings
or to standard management based on history and clinical
examination [24]. In addition to NICE [9–12] and the
Cochrane Collaboration [24], the National Institute for
Health Research - Health Technology Assessment
programme (NIHR-HTA) [25] and the International
Consultations on Incontinence (ICI) [26, 27] have also
reviewed research literature on urodynamics, and, along
with the James Lind Alliance Urinary Incontinence Priority
Setting Partnership [28, 29], have called for high quality
primary research assessing their clinical utility.
But several considerations indicated the need for a pilot
trial and feasibility assessment before undertaking a defini-
tive trial. The first consideration is the calculation of an in-
formed sample size. Calculations based on estimates and
assumptions from previously published modelling exercises
[9, 30] and a previous surgical trial [31, 32] are sensitive to
parameter values such as the proportion of recruits with
SUI [30], the proportions of poor outcomes in the two
arms, and the effect size (target difference) of interest.
Calculations based on data in the most recent Cochrane
review of urodynamics indicates that a sample size of over
1,600 per arm would be required to address this question
[24]. Therefore, given the possible size and cost of a defini-
tive trial, a pilot trial was considered crucial to test the as-
sumptions made, give relevant estimates of key parameters,
and ensure that a definitive trial would represent value for
money from public funds. Secondly, a feasibility assessment
could establish whether sufficient clinicians are willing to
randomise patients within a definitive trial. IUTs have been
widely used in clinical practice over the last 30 years, and
despite the lack of evidence of clinical utility, many clini-
cians look on cystometry as a mandatory part of the investi-
gation of patients with UI, particularly prior to surgical
treatment [33–35]. A survey of members of the British
Society of Urogynaecology (BSUG) has shown a high level
of disagreement with the NICE guidance in this respect
[36], and others have questioned the safety of the recom-
mendations [37]. Finally, a key feasibility objective was to
assess patient willingness to participate and identify barriers
to and facilitators of participation. Patients may not so eas-
ily see the importance of ‘testing a test’ in the same way as
they might view testing a treatment. Women may be willing
to undergo even invasive investigation [38] in the belief that
this will inevitably guide them and their clinicians towards
appropriate treatment, and away from inappropriate and
possibly harmful interventions. In a pilot patient preference
study, only 32 % of the women were prepared to be
randomised [38].
Recognising that a pilot randomised controlled trial
(RCT) alone was probably inadequate to address the
complexities of feasibility for a definitive trial in this as-
pect of healthcare, the INVESTIGATE-I study com-
prised an external pilot RCT, an exploratory health
economic analysis and value of information study, a na-
tional survey of relevant clinicians, and separate quali-
tative interview studies with patients eligible for the
trial and clinicians responding to the survey. Only the
first and second of these elements are reported here.
The original study protocol was published in this journal
[39]; two later amendments were approved by the
Research Ethics Committee, and the final version of the
protocol (v1.2) is available on the NIHR website http://
www.nets.nihr.ac.uk/projects/hta/0922136. The clinician
survey and interview study have been published in full
previously [40, 41], and a separate publication is planned
for the economic evaluation and value of information
study [42]. This report therefore, whilst drawing conclu-
sions from the whole collection of studies, focuses on the
pilot trial itself, and the qualitative interview study with
trial participants.
Methods
The conduct of this study was in accordance with the
ethical principles set out in the Declaration of Helsinki
(2008) and the Research Governance Framework for Health
and Social Care (second edition, 2005) [43]. Application for
ethical approval was made through the Integrated Research
Application System (IRAS), and a letter of favourable
ethical opinion was obtained from Newcastle & North
Tyneside 1 Research Ethics Committee on 6th January
2011 - reference no. 10/H0906/76. All elements of the
study were approved by local Research and Development
offices at Newcastle upon Tyne Hospitals NHS Foundation
Trust (28/03/2011), Gateshead Health NHS Foundation
Trust (29/03/2011), Abertawe Bro Morgannwg University
Health Board (23/06/2011), Sheffield Teaching Hospitals
NHS Foundation Trust (07/07/2011), Northumbria Health-
care NHS Foundation Trust (25/07/2011), University
Hospitals of Leicester NHS Trust (09/08/2011), City Hospi-
tals Sunderland NHS Foundation Trust (30/05/2012),
South Tees Hospitals NHS Foundation Trust (09/07/2012)
and South Tyneside NHS Foundation Trust (17/09/2012);
hence the favourable ethical opinion was applicable to all
NHS sites taking part in the study.
The objective of the feasibility study (INVESTIGATE-I)
was to inform the decision as to whether to proceed to a
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definitive RCT of the clinical and cost-effectiveness of IUT
compared to basic clinical assessment with non-invasive
testing in women potentially suitable for surgical treatment
of SUI or stress predominant MUI and whether any refine-
ments to the proposed definitive trial design were war-
ranted [44–48].
Pragmatic multicentre randomised pilot trial
The pilot RCT was designed to rehearse the methods
and processes of any future definitive RCT.
Units recruiting to the trial
Recruitment to the pilot trial was initially limited to six spe-
cified units; these were a mix of specialist urogynaecology
(Newcastle upon Tyne and Leicester) and female urology
(Sheffield and Swansea) departments in university teaching
hospitals, providing secondary and tertiary level care, and
general gynaecology units in district general hospitals, pro-
viding secondary care services (Wansbeck Hospital, North-
umberland, and Queen Elizabeth Hospital, Gateshead).
In order to improve adherence with recruitment tar-
gets and to test the processes for possible future use,
two Patient Identification Centre (PIC) sites (Sunderland
Royal Hospital and South Tyneside District General
Hospital) and one additional full recruiting site (South
Tees Hospitals NHS Foundation Trust) were added in
2012.
Inclusion and exclusion criteria
Inclusion criteria Inclusion criteria for the pilot RCT
(and anticipated inclusion criteria for any future definitive
RCT) were as follows:
1. Clinical diagnosis of SUI or stress-predominant MUI.
2. Women must state that their family is complete.
3. Women should have undergone a course of pelvic
floor muscle training (± other non-surgical treatments
for their urge symptoms) with inadequate resolution
of their symptoms.
4. Both the woman and her treating clinician should
agree that surgery is an appropriate and acceptable
next line of treatment.
Exclusion criteria Exclusion criteria for the pilot RCT
(and anticipated exclusion criteria for any future defini-
tive RCT) were as follows:
1. Symptomatic utero-vaginal prolapse requiring
treatment.
2. Previous surgery for urinary incontinence or pelvic
organ prolapse.
3. Urodynamic investigation within the last three years.
4. Neurological disease causing urinary incontinence.
5. Current involvement in competing research studies,
for example, studies of investigation or treatment of
urinary incontinence.
6. Unable or unwilling to give competent informed
consent.
Recruitment
Potential trial recruits were identified by research nurses
prior to attending new or follow-up appointments for SUI
or MUI. A short Patient Information Leaflet (PIL) was
Xincluded with a letter of invitation, with new appoint-
ments or reminder letters for follow-up appointments. A
full (6-page) PIL was provided on request. The study infor-
mation was discussed at the first hospital visit; women de-
clining to take part underwent further investigation and or
treatment as clinically appropriate at the same visit. Written
consent was obtained from those agreeing to take part, be-
fore randomisation. To ensure concealment of allocation,
randomisation was undertaken by an internet-accessed
computer randomisation system held by the Newcastle
Clinical Trials Unit (NCTU); randomisation between inter-
vention and control was 1:1, and was stratified by centre
using random block length. It was neither feasible nor
appropriate to blind participants or clinicians (investigating
and operating) to the allocation of the investigation
strategy.
Sample size
The sample size for the external pilot trial was determined
pragmatically, using the recommended minimum of 30 par-
ticipants per arm. [47] It was hoped that 60 would be
retained per trial arm to investigate the distribution and key
parameters of the outcome measures. Previous trials in the
area of pelvic floor dysfunction, including investigation
[49], surgical [32, 50, 51], and non-surgical treatments [52]
suggested average attrition rates of 13 % (7–20 %) between
identification and randomisation, 16 % (6–20 %) between
randomisation and treatment, and 13 % (9–20 %) between
treatment and follow-up at 6 months. Based upon the more
pessimistic figure in each case, it was estimated that a total
of 240 eligible patients should be approached, allowing for
a 50 % overall attrition.
Interventions
Patients were randomised to receive either of the following:
1. No IUT - basic clinical assessment supplemented by
non-invasive tests as directed by the clinician; these
included frequency/volume charting or bladder diary,
mid-stream urine culture, urine flow rate and residual
urine volume measurement (by ultrasound), or
2. IUT - basic clinical and non-invasive tests as above,
plus invasive urodynamic testing (IUT). Dual-channel
subtracted cystometry with simultaneous pressure/
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flow voiding studies is the most commonly applied
technique in the evaluation of patients prior to surgery
for SUI in most centres; video-urodynamics and ambu-
latory bladder pressure monitoring were also permis-
sible at the discretion of the clinician.
Further investigation was undertaken where appropriate
at the same visit or a later one, as per local practice, and
the treatment plan formulated.
Outcome measures
The collection of the outcome measures for a future de-
finitive RCT was piloted, to assess data yield (for example,
percentage of recruited participants returning completed
questionnaires) and quality (for example, completeness
and consistency of responses within returned question-
naires). This information was collected to guide the choice
and mode of administration of questionnaires and data
collection tools in any future definitive RCT.
The primary outcome rehearsed in the pilot RCT was
a patient-reported outcome measure (PROM):
1. The combined symptom score of the International
Consultation on Incontinence - female lower urinary
tract symptoms questionnaire (ICIQ-FLUTS) at 6
months after treatment [31].
Secondary outcomes rehearsed were as follows:
1. General health questionnaire (SF-12v2™ Health
Survey © 1994, 2002 by QualityMetric Incorporated
and Medical Outcomes Trust) [53], and EQ-5D-3 L
© 1990 by EurQol Group [54])
2. Quantification of urinary leakage (three day bladder
diary, and ICIQ-UI SF) [55]
3. Prevalence of symptomatic ‘de novo’ functional
abnormalities including voiding dysfunction and
detrusor overactivity (using subscales in ICIQ-
FLUTS [31], with cystometric investigation in
symptomatic patients)
4. The impact of urinary symptoms on quality of life
(ICIQ-LUTSqol and UDI) [56, 57]; the latter
measure was included since it was used in the
VUSIS and VALUE trials [18, 19].
5. Use of health services and costs to the NHS and to
patients
Baseline assessment of study outcomes
Following consent and randomisation, patients were given
a pack of baseline study outcome questionnaires. Partici-
pants were asked to complete the questionnaires at home
within 2 weeks of receipt and post them to the central trial
office using a prepaid envelope.
Subsequent treatment within the trial
Following investigation, it was expected that women
randomised to the ‘no IUT’ arm of the study would
undergo surgical treatment. The choice of operation was
left to the individual surgeon and woman; because only pri-
mary cases were included, it was anticipated that in most
cases this would be either a retropubic or transobturator
foramen mid-urethral tape procedure. It was expected that
those randomised to the intervention ‘IUT’ arm would have
similar surgical treatment when urodynamic stress incon-
tinence (USI) was confirmed. Where other diagnoses were
identified following investigation, alternative treatments
might be offered, which were informed by which other
conservative treatments had previously been tried. These
included bladder retraining, anti-muscarinic drug treat-
ments, neuromodulation, botulinum toxin injections
(where detrusor overactivity (DO) was diagnosed), or
clean intermittent self-catheterisation (where a voiding
dysfunction was identified). In all centres, the treatment
algorithm employed was in keeping with the then current
NICE recommendations (2006) [9].
Follow-up
Clinicians arranged post-operative follow-up or other out-
patient review, as per their normal practice and timing.
Women were sent a pack of follow-up study outcome
questionnaires and bladder diaries along with a prepaid
envelope at 6 months after surgery, at the start of any
non-surgical intervention, or at a period of ‘watchful wait-
ing’. They were asked to complete and then post them to
the central trial office. Those failing to return question-
naires within 1 month were contacted by a research nurse
by telephone to encourage responses. In the last 9 months
of the study, the option of completing the questionnaire
over the telephone with the research nurse was also given
to participants during the reminder telephone call. Those
who did not return the questionnaires after a telephone
reminder were sent a second copy of the questionnaires.
Each patient’s withdrawal or completion of the study
follow-up was documented in the case report form (CRF).
Qualitative interviews with women eligible for the
pilot trial
Interviews were carried out to explore the women’s under-
standings and experiences of the study, including the con-
sent processes and their decision to participate. Purposive
sampling was used to invite women from a range of ages,
trial participation status (randomised and retained to final
follow-up; randomised but did not provide full follow-up
data), allocation status (IUT or basic assessment), treat-
ment received (surgery or conservative management), and
study site. It was also intended that women who declined
randomisation would be interviewed.
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Women were approached at the end of the trial so as to
capture both their reasons for agreeing to participate and
their overall experience of taking part in the study. A spe-
cific Participant Information Leaflet was provided for the
interview study, and written consent was obtained from all
interviewees. The interviews were carried out face-to-face
by an expert qualitative interviewer (see acknowledge-
ments) and were audio-recorded and transcribed verbatim.
The interviews were semi-structured, using a prompt
guide with broad topic areas, but the emphasis was on en-
couraging women to discuss their own perspectives freely,
thereby allowing them to raise issues that were important
to them. The interviewer prompted as appropriate to
ensure that all views were fully explained and the meaning
of participants’ responses clear. The prompt guide was
developed from a literature review and discussions within
the project team and was modified as the interviews pro-
gressed to incorporate issues raised by earlier interviewees.
Analysis took place alongside data collection, which
continued until saturation of themes was reached and in-
terviews no longer generated new concepts. All completed
interviews were included in the analysis. Analysis was
based on the constant comparative method [58], and
aided by NVivo 10 software (© QSR International, War-
rington, UK). Data analysis was carried out by an experi-
enced qualitative researcher (see acknowledgements)
under the supervision of NA. To maximise the credibility
and rigour of the analysis, NA regularly reviewed the cod-
ing scheme and interview transcripts, and any differences
in interpretation were discussed and reconciled. Further
details of the methods are published in full in the protocol
document [39, 59].
Synthesis of findings
The analytic framework proposed by Bugge et al. [45]
was used to summarize findings from the pilot trial
and participant interviews; this framework comprises
14 methodological issues, derived from the work of
Shanyinde et al. [60] on what needs to be evaluated
in pilot and feasibility studies.
This analysis is followed by the 3-step ADePT process,
involving:
1. Deciding on the type of problem experienced (Type A
- the issue is likely to be a problem only for the trial;
Type B - the issue is likely to be a problem for both
the trial and the real world; Type C - the issue is likely
to be a problem only for the real world), and the
associated evidence;
2. Identifying the range of possible solutions and the
evidence to support those solutions, including
assessment of the potential effectiveness and
potential feasibility of each option;
3. Assessing the best options.
Results
The summary of methodological issues [60], and their
analysis after Bugge et al. [45], is given in Table 1.
Pragmatic multicentre randomised pilot trial
Screening, recruitment and randomisation
The screening, recruitment, randomisation and trial follow-
up are summarised in the CONSORT diagram shown as
Fig. 1. Overall, 771 women were identified and were sent
the patient information sheets. Of those, 284 were deemed
eligible for the trial, (37 % screen positive). The reasons for
non-eligibility, which varied between centres, are shown
below in Table 2. One centre accounted for more than half
the women screened (399; 52 %).
Of the 284 women screened positive, 222 agreed to ran-
domisation into the trial, giving a trial consent rate of 78 %.
This recruitment total (222) represented 93 % of the
planned sample size (240) for the pilot trial. Overall, 110
women were randomised to the ‘no IUT’ arm and 112 to
the ‘IUT’ arm. Immediately after randomisation, it became
apparent that one woman in the ‘no IUT’ arm was ineligible
for the trial, and she was withdrawn leaving a total of 221
eligible patients randomised (109 in the ‘no IUT’ arm and
112 in the ‘IUT’ arm).
Monthly recruitment is shown in Fig. 2. Regulatory re-
quirements took approximately 3 months longer than
anticipated, and recruitment targets were revised accord-
ingly. The rate of accrual over time was significantly less
than required; several steps were introduced to improve
recruitment, including the incorporation of additional clini-
cians at two of the existing sites, and the establishment of
an additional full recruiting site and two Participant Identi-
fication Centre (PIC) sites; a 9-month unfunded extension
to the recruitment period was agreed upon with the study
funder. Newsletters reporting the progress of the pilot RCT
and regular recruitment updates were provided to clinicians
in order to maintain their engagement.
The number of participants recruited per recruiting
month (that is, between the completion of all site specific
regulatory requirements and the end of the study) varied
between 0.4 and 3.9 per month at the original sites (mean
1.9); at the additional full recruiting site this figure was 2.5
per month; the PICs did not identify any potentially eli-
gible patients for referral to a recruiting site in the eight
months that they were active.
Table 3 provides the demographic data by trial arm; the
consistency of these variables between ‘IUT’ and ‘no IUT’
arms confirms the validity of the randomisation process.
Retention
Two women in the ‘IUT’ group withdrew because they
were unhappy with their allocation. Baseline questionnaires
were sent to 219 women and returned by 165 (a 75 %
response rate overall, 72 % ‘IUT’ arm and 79 % ‘no IUT’
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Table 1 Summary of findings against 14 methodological issues for feasibility research
Methodological issue Findings Evidence
1. Did the feasibility/pilot study allow
a sample size calculation for the
main trial?
Achieved: a definitive trial would require recruitment
of between 232 (for a target difference of four units
in ICIQ-FLUTS score at 6 months) and 922 (for a target
difference of two units) patients, to achieve a sample
of 130 to 516 primary outcome responses.
Observed standard deviation for difference in ICIQ-
FLUTS = 7.
Observed retention rate of 63 %.
2. What factors influenced eligibility
and what proportion of those
patients approached were eligible?
37 % of those approached and assessed screened
positive.
Of 771 women identified and approached, 284 were
(37 %) were deemed eligible.
Main reasons for ineligibility (see Table 2) were as
follows:
• Patient has not undergone a course of pelvic floor
training
• Urge incontinence
• Patient did not attend clinic
3. Was recruitment successful? Recruitment was slower than anticipated The mean rate of recruitment per open site month at
original sites was 1.9, with a recruitment rate per open
site month at the additional full recruiting site of 2.5.
In 8 months, the PICs did not identify any potentially
eligible patients
4. Did eligible participants consent? Largely achieved, with a recruitment total of 222,
representing 93 % of the target of 240.
Of the 284 women who screened positive, 222 (78 %)
consented to randomisation
5. Were participants successfully
randomised and did randomisation
yield equality in groups?
Achieved Overall, 110 women were randomised to the control
arm and 112 to the intervention arm.
Baseline comparability of the two groups was
adequate (Tables 3 and 4)
6. Were blinding procedures
adequate?
Not applicable - non-blinded design
7. Did participants adhere to the
intervention?
Largely achieved In the control group, one woman was found to be
ineligible post-randomisation and was withdrawn. The
remaining 109 received no IUT.
In the intervention group, 102 of the 112 women
randomised (91 %) received IUT. 2 withdrew because
they were unhappy with their allocation, 1 did not
attend for cystometry, 3 withdrew for other reasons,
and 4 did not receive IUT.
8. Was the intervention acceptable
to participants?
Mixed findings; 59 eligible women did not wish to be
randomised. Qualitative interviews provided insights
into preferences of those consenting to
randomisation.
Although most eligible women were willing to be
randomised, some had a previously undeclared
preference for avoiding IUT and expressed relief at
being allocated to the control group. These data will
be reported separately elsewhere.
We did not succeed in interviewing any women who
did not consent to the trial.
9. Was it possible to calculate
intervention costs and duration?
We have demonstrated that meaningful and usable
data were collected using the instruments we
designed for this purpose, and it is feasible to
calculate intervention costs based on data collected
and from reference costs information. These data will
be reported separately elsewhere.
Questionnaires and CRF pages designed to collect
relevant information for costs calculation performed
reasonably well, with a good response rate and low
level of missing data. The average total cost per patient
is £1815.26 (SD: 210.39) for ‘IUT’ arm and £1775.37 (SD:
455.38) for ‘no IUT’ arm, based on complete cases only.
The mean duration of ‘IUT’ was 40 minutes (SD: 11.028)
10. Were outcome assessments
completed?
Mixed picture with poorer completion of outcome
assessments at 6 months.
75 % of women returned baseline questionnaires and
63 % returned 6-month questionnaires. Of those who
returned questionnaires, some returned incomplete or
blank questionnaires
Bladder diaries and pad use data were poorly
completed.
Baseline full completion rates:
ICIQ-FLUTS: 98 %
ICIQ-UI SF: 99 %
ICIQ-LUTSqol: 95 %
UDI overall score: 84 %
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arm). At the 6-month follow-up, questionnaires were
returned by 63 % (125/200), (56 % (54/97) ‘IUT’ arm and
69 % (71/103) ‘no IUT’ arm).
Completeness of data collection
Not all women fully completed each questionnaire
although missing values within individual scales were
few. The columns to the right-hand side of Table 4
show the proportion of each questionnaire or subscale
that could be calculated from the data provided.
Comparison of responders and non-responders to 6-month
questionnaire
Given the high rate of non-response to the 6-month ques-
tionnaires, a comparison of responders and non-
responders was made on the basis of their clinical follow-
up. A total of 135 women had a postoperative follow-up
visit documented on the study database; 93 actually
attended an outpatient clinic, and 42 had a review by tele-
phone (routine practice in three of the centres).
Of the 125 women who returned follow-up question-
naires at 6 months after treatment, 83 had clinical follow-
up; of these, 12/83 (14.5 %) described bothersome urinary
symptoms, and 9/83 (10.8 %) had clinically significant
examination findings. Of the 81 who failed to return
follow-up questionnaires at 6 months, 52 had clinical
follow-up, of whom 5/52 (9.6 %) described significant
urinary symptoms, and 4/52 (7.7 %) had clinically signifi-
cant examination findings.
Whilst those women returning the 6-month question-
naires had bothersome symptoms or clinically significant
examination findings at clinical review somewhat more
often than those failing to do so, the numbers do not
allow meaningful statistical comparison.
Questionnaire data
Baseline
Table 4 shows the distribution of the questionnaire scales
at baseline by trial arm. The distribution of ICIQ-FLUTS
total score at baseline was fairly symmetrical with a mean
of 16.9 (SD 5.7) in the ‘IUT’ arm and 16.4 (SD 6.3) in the
‘no IUT’ arm. The distributions of the other scales and
subscales were similarly well matched between the ‘IUT’
and ‘no IUT’ arms and were fairly symmetrical.
Six-month follow-up
Table 4 also shows the distribution of the questionnaire
scales at the 6-month follow-up by trial arm. For all scales,
typical scores were much lower than at baseline. It is
difficult to interpret any difference in mean scores between
baseline and the 6-month follow-up from Table 4, because
of the small sample size and the number of women who
provided baseline data but for whom no 6-month question-
naire data are available. Table 5 shows the distribution of
the paired changes in scale scores for those women who
had completed both questionnaires. It can be seen that the
mean change in ICIQ-FLUTS total score was 7.8 in the
‘IUT’ arm and 9.3 in the ‘no IUT’ arm. Typically, there was
a marked drop in these scores over 6 months, but little
difference in the mean changes between the trial arms; this
pattern was also seen in the other four scales, although no
formal comparison between arms is appropriate in a
pilot study.
Table 1 Summary of findings against 14 methodological issues for feasibility research (Continued)
6-month full completion rates:
ICIQ-FLUTS: 90 %
ICIQ-UI SF: 91 %
ICIQ-LUTSqol: 87 %
UDI overall score: 81 %
11. Were outcomes measured those
that were the most important?
Some evidence from patient interviews that women
were less likely to return questionnaires if they were
satisfied with the results of treatment
Lower response rates for instruments towards the end
of questionnaire booklet
12. Was retention to the study
good?
Rates of loss to follow-up were significant 75 % of women had face-to-face or telephone follow-
up after surgical treatment, but only 56 % (63 % of
those circulated) returned follow-up questionnaires at
6 months.
13. Were the logistics of running a
multicentre trial assessed?
Achieved. Some centres performed better than
others, and PICs were not fruitful.
The need to build in adequate time for obtaining
global and local approvals was identified
14. Did all components of the
protocol work together?
Achieved - components had good synergy No significant differences identified with trial
processes or researchers’ abilities to implement them
CRF, case report form; ICIQ-FLUTS, International consultation on incontinence questionnaire-female lower urinary tracts symptoms; ICIQ-LUTSqol-ICIQ, lower
urinary tract symptoms quality of life; ICIQ-UI SF-ICIQ, urinary incontinence-short form; IUT, invasive urodynamic testing; PIC, patient identification centre; UDI,
urogenital distress inventory; SD, standard deviation
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Treatment data
In the ‘IUT’ arm, 82 women (80 %) received surgery, com-
pared to 103 (95 %) in the ‘no IUT’ arm. The distributions
of operation type, grade of surgeon, anaesthetic technique
and use of antibiotic prophylaxis were similar between the
trial arms.
One woman in the ‘no IUT’ arm and four (4 %) in the
‘IUT’ arm decided to defer any treatment initially (desig-
nated as ‘watchful waiting’). A further 15 women (15 %) in
the ‘IUT’ arm underwent lifestyle changes or other non-
surgical treatments. As routine in continence manage-
ment, more than one lifestyle change was commonly
documented, and other non-surgical treatments were
often used in combination; 28 treatments were applied in
these 15 women. Despite prior (unsuccessful) completion
of a course of supervised pelvic floor muscle training
(PFMT) being an inclusion criterion for the trial, six
women underwent further PFMT alone (n=2) or in com-
bination with other non-surgical treatments (n=4).
Adverse and serious adverse events
Only two serious adverse events were reported. One
woman in the ‘IUT’ arm experienced bleeding from the
sub-urethral incision 12 days after surgery and one woman
Fig. 1 Trial CONSORT flow diagram. IUT, invasive urodynamic testing (intervention) arm; no IUT, no invasive urodynamic testing (control) arm; DNA, did
not attend
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in the control arm was treated for breast cancer by mastec-
tomy shortly after her surgery within the trial; whilst the
first was clearly related to the incontinence treatment, nei-
ther event was categorised as being related to the trial inter-
vention (IUT).
In addition, 23 adverse events were reported in 22
women; these included three operative bladder injuries
(3/185=1.6 % perforation rate) and two vaginal injuries.
Six episodes of urinary tract infection (UTI) were re-
ported, two in the ‘IUT’ arm and four in the ‘no IUT’
arm; all occurred following surgery, and none occurred
immediately after IUT.
Calculation of potential sample size of definitive trial
Based upon the trial results, the study team decided that
differences of 2, 3 or 4 units on the ICIQ-FLUTS scale
would be realistic and potentially clinically important
differences that might be achieved.
Given these estimates of effect size, a standard deviation
of 7 for paired changes between baseline and follow-up,
Type I error of 5 % and Type 2 error of 10 %, total sample
size estimates for any definitive trial fall between approxi-
mately 200 and 900 women recruited (Table 6). These
estimates are considerably less than calculations based
upon data in the most recent Cochrane review of uro-
dynamics, which indicate that a sample size of over 1,600
per arm would be required to address this question [24].
With a recruitment rate of 78 %, recruitment of between
200 and 900 would require between approximately 300
and 1200 eligible women to be approached; in turn, with a
screen positive rate of 37 %, this would mean between
approximately 800 and 3,000 women would need to be
identified for screening for eligibility; these ranges depend
upon the effect size.
Patient interview study
All 59 eligible women who declined to participate in the
pilot trial were invited to interview but none was willing.
A diverse sample of 111 pilot trial participants was
invited to take part in the interview study, including par-
ticipants from different study sites, the two study arms, a
wide range of ages, and those who did and did not
complete all follow-up. A total of 36 women indicated they
were willing to be interviewed, but of these, two withdrew
from the interview study before the interview could be
arranged and another had moved and so was no longer
covered by our research governance approvals. Of the
remaining 33 women, 29 were interviewed before satur-
ation of themes was reached, and the last four were not
interviewed as they were from groups already well repre-
sented in the sample. Interviewees were between 35 and 75
years of age, came from five of the seven full trial centres,
and included participants from both ‘IUT’ (16) and ‘no
IUT’ (13) arms.
The invitation to participate, and reasons for agreeing
Women’s first reactions to receiving the invitation to
participate in the pilot study were almost exclusively posi-
tive. The decision to take part was commonly made
quickly and easily, and very few reported feeling the need
to talk with family or friends as part of the decision-
making process.
WAS IT AN EASY DECISION TO MAKE?
Yes, very.
DID YOU MAKE IT ON YOUR OWN?
Yes, (Participant 10)
As is commonly found in other studies [61–63], many
women’s reasons for participation were altruistic and
included wanting to help research, to help others with the
Table 2 Screening & recruitment numbers including screening
codes (1-15) for those women not randomised, sorted by
overall frequency of reporting of codes
Code Description Total Per cent
11 Patient has not undergone a course
of pelvic floor training
105 14 %
14 Urge incontinence 92 12 %
13 Other (give details) 86 11 %
15 Patient did not attend clinic 81 11 %
7 Patient does not wish to participate,
include reason if offered
59 8 %
1 Symptomatic utero-vaginal prolapse
requiring treatment
40 5 %
8 Clinician feels surgery inappropriate 39 5 %
9 Patient does not wish surgery 21 3 %
2 Previous surgery for urinary incontinence
or pelvic organ prolapse
9 1 %
3 Urodynamic investigation within the last
three days
7 1 %
10 Patient does not consider her family is
complete
6 1 %
4 Neurological disease causing urinary
incontinence
1 0 %
5 Current involvement in a conflicting
research study
0 0 %
6 Unable to give competent informed
consent
0 0 %
12 Study not discussed at clinic visit
(please give reason)
3 0 %
Recruited 222 29 %
Total screened 771 100 %
Screened women
recruited
222/
771
29 %
Eligible women
recruited
222/
284
78 %
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same condition, and to make some form of repayment for
the help and treatment they were receiving.
Participating in the pilot did not seem to require a lot
from them, so no particular participation burden was
perceived.
She explained it very clearly and said all it is
basically is just to monitor how many times you go
to the toilet, and how much you drink, and roughly
how much your output was. And to me I thought
that wasn’t a big problem. Only a few minutes of
your time in your day, just to keep track.
(Participant 04)
The information provided about the study
Reactions to the written information were mostly positive
- it was regarded as clear and informative, and there was
enough information for women to be able to make a deci-
sion about taking part. The short version was sufficient for
some and the flow diagram was popular. Others liked to
have the fuller detail in the longer version. Overall, most
people found it helpful, describing it as easy to read, in-
formative, and pitched at the right level.
So everything was really well explained you know, so
yeah I mean I can’t fault it really, no I was well
impressed with it all. (Participant 25)
Table 3 Summary of demographic data at baseline by trial arm
IUT no IUT
n % n %
Ethnicity
Caucasian 110 99 % 106 97 %
Black 0 0 % 0 0 %
Asian 1 1 % 3 3 %
Other 0 0 % 0 0 %
IUT no IUT
n mean (SD) median (IQR) range n mean (SD) median (IQR) range
Age 112 47.1 (9.5) 46.5 (40–52) 29–75 110 46.8 (10.0) 46.5 (40–52) 24–77
BMI 106 29.3 (6.5) 28.3 (24.4–33.7) 20–55 102 27.4 (5.0) 26.8 (23.9–30.7) 18–45
BMI, body mass index; SD, standard deviation; IQR, interquartile range; IUT, invasive urodynamic testing (intervention) arm; no IUT, no invasive urodynamic testing
(control) arm
Fig. 2 Monthly target and actual recruitment numbers. The original and revised predictions of overall recruitment are shown as continuous and dashed
lines, and actual recruitment in histogram; the overall Comprehensive Local Research Network (CLRN) black/red/amber/green flag or ‘recruitment to target’
status is also illustrated
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Table 4 Summary of numeric outcome measures by trial arm and data collection time-point
IUT no IUT Overall completion ratea
Baseline 6 months Baseline 6 months Baseline 6 monthsb
Questionnaire
(possible scores)
n Mean (SD) Median
(IQR)
Range n Mean
(SD)
Median
(IQR)
Range n Mean (SD) Median (IQR) Range n Mean
(SD)
Median
(IQR)
Range Partial
n (%)
Complete
n (%)
Partial
n (%)
Complete
n (%)
ICIQ-FLUTS
Overall
score (0–48)
77 16.9 (5.7) 17 (13–21) 4–37 47 9.2 (7.5) 8 (4–12) 0–38 85 16.4 (6.3) 16 (11–21) 3–34 66 6.9 (5.0) 6 (3–9) 0–26 3 (2) 162 (98) 5 (4) 113 (90)
Subscales:
Filling
(0–16)
78 4.4 (2.3) 4 (3–6) 0–11 48 3.0 (2.3) 3 (1–4) 0–11 85 4.0 (2.6) 3 (2–6) 0–10 66 2.4 (1.8) 2 (1–3) 0–8 2 (1) 163 (99) 3 (3) 114 (91)
Voiding
(0–12)
79 1.8 (2.0) 1 (0–3) 0–9 49 2.0 (2.0) 2 (0–3) 0–9 86 1.5 (1.7) 1 (0–2) 0–9 68 2.3 (2.1) 2 (0–4) 0–8 0 (0) 165 (100) 1 (1) 117 (94)
Incontinence
(0–20)
78 10.8 (3.3) 11 (8–13) 2–19 49 4.0 (4.9) 3 (1–5) 0–20 86 10.8 (3.6) 11 (8–13) 2–19 68 2.3 (3.1) 2 (0–3) 0–16 1 (1) 164 (99) 1 (1) 117 (94)
ICIQ-UI SF
(0–21)
78 14.0 (3.7) 14 (12–16) 4–21 49 5.3 (6.0) 3 (0–8) 0–21 85 14.1 (3.8) 15 (12–17) 4–21 65 3.3 (4.5) 1 (0–4) 0–18 2 (1) 163 (99) 3 (3) 114 (91)
ICIQ-LUTSqol
(19–76)
73 46.8 (10.9) 47 (40–52) 26–74 44 26.7 (12.3) 22 (20–28) 19–76 84 48.5 (11.7) 46 (39–58) 30–72 65 25.3 (9.6) 21 (20–28) 19–65 8 (5) 157 (95) 9 (7) 109 (87)
UDI
Overall score
(0-300)
64 133.3(43.5) 133.5(109–159) 25–245 42 49.1(44.1) 37.1(17–69) 0–191 74 130.1 (43.8) 125.8(96–162) 50–227 59 33.9 (39.7) 24.2 (4–46) 0–150 27 (16) 138 (84) 17 (14) 101 (81)
Subscales:
Stress
(0–100)
76 82.9 (21.0) 87.5 (75–100) 25–100 50 24.5 (26.1) 25 (0–38) 0–100 80 80.2 (21.2) 87.5 (63–100) 38–100 65 18.1 (27.0) 0 (0–25) 0–100 6 (4) 156 (95) 2 (2) 115 (92)
Irritative
(0–100)
71 38.4 (25.4) 33.3 (17–54) 0–100 48 16.5 (20.5) 8.3 (0–25) 0–100 80 33.7 (24.3) 31.3 (17–50) 0–92 64 10.0 (13.3) 4.2 (0–17) 0–54 13 (8) 151 (91) 6 (5) 112 (90)
Obstructive/
discomfort
(0–100)
68 17.6 (17.6) 13.6 (6–23) 0–73 43 10.9 (15.1) 4.6 (0–18) 0–64 80 14.8 (14.2) 13.6 (3–20) 0–61 64 8.9 (12.4) 2.3 (0–14) 0–57 17 (10) 148 (90) 11 (9) 107 (86)
ICIQ-FLUTS, International Consultation on Incontinence Female Lower Urinary Tract Symptoms questionnaire; UDI, Urogenital Distress Inventory; SD Standard deviation; IQR Interquartile range; IUT, invasive urodynamic
testing (intervention) arm; no IUT, no invasive urodynamic testing (control) arm
aComplete responses are defined as women who completed all questions on the particular questionnaire scale, and partial responses as those who completed at least one question but did not fully complete the
particular scale
bIn addition to complete and partial responses, there were seven completely blank questionnaires among the 6-month responses
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The use participants made of the material varied -
some read it once only or just skimmed it, others read it
more than once, and a small number did additional re-
search about the study on the internet.
I think I just read it, I didn’t take too much in I think,
I think I was just so looking forward to getting my
operation that is all I was really erm… really bothered
about. I don’t think I read too much about the ins and
outs of the study. (Participant 20)
Basically I just went on-line and looked at the various
things and just erm… just looked at the study.
(Participant 15)
Some were happy with the verbal information at the
time of their consultation and paid little attention to the
written material, particularly the longer version.
Personally I wouldn’t bother with the big one, I think
that there is enough information, and if you get good
medical staff to start with like I did, who actually took
the time to go through it with you and say this is what
this says, now read it on there, erm… so I think if you
get that then you certainly don’t need the bigger one.
(Participant 07)
Suggestions for how the information might be im-
proved were limited but included keeping it as short and
concise as possible and distributing it prior to the con-
sultation because some women reported feeling anxious
at the consultation and did not initially pay much atten-
tion to the information. Given that some women valued
the verbal information they received from clinical staff
more than the written information, being able to go to
the consultation with questions prepared may have been
helpful.
Understanding of the study
Participants’ understanding of the study was broadly
good, although there were some cases in which people
appeared confused about the overall aim. Overall, there
was a generally good understanding that the study was
assessing the value of a particular diagnostic test rather
than the treatment they would ultimately receive. Many
talked explicitly about how, while participation in the
study could influence the route they took to treatment,
it was ultimately unlikely to change the final outcome.
Establishing this was often important to securing their
participation.
I remember asking him ‘so if I don’t have the test will it
have any effect on any treatment I have, and will it
have any effect on you deciding what I need?’ No he
said, it was purely for this investigation. (Participant 22)
Not all participants understood the study in this way,
though. A small number, when asked to explain what
they thought the study was about, did focus on the sub-
sequent treatment rather than the invasive testing.
I think it's about finding the right appropriate erm…
ways forward to treat people with urinary problems.
Erm… whether surgery or invasive treatment is
appropriate or whether there is another kind of treatment
that might be more beneficial. (Participant 17)
The principle of random allocation to one of two pos-
sible groups was generally well understood. There were,
Table 5 Summary statistics for paired changes in scale scores
(from baseline to 6 months)
Questionnaire n Mean
(SD)
Median (IQR) Range
‘IUT’ arm
ICIQ-FLUTS - Overall
score
31 7.8 (5.9) 7 (4 to 15) -5 to +18
ICIQ-UI SF 34 8.9 (6.0) 11 (4 to 13) -3 to +16
ICIQ-LUTSqol 29 20.0
(11.4)
23 (12 to 28) -5 to +41
UDI - Overall score 27 79.5
(45.5)
75 (51 to 122) -21 to
+161
‘no IUT’ arm
ICIQ-FLUTS -Overall
score
48 9.3 (7.3) 10.5 (5.5 to
15)
-9 to +22
ICIQ-UI SF 49 10.2 (5.8) 11 (6 to 15) -4 to +21
ICIQ-LUTSqol 47 23.7
(13.9)
23 (14 to 35) -3 to +50
UDI - Overall score 41 94.1
(55.3)
92 (70 to 117) -66 to
+221
ICIQ-FLUTS, International Consultation on Incontinence modular questionnaire
- Female Lower Urinary Tract Symptoms questionnaire; ICIQ-UI SF, ICIQ Urinary
Incontinence Short Form questionnaire; ICIQ-LUTSqol, ICIQ Lower Urinary Tract
Symptoms quality of life questionnaire; UDI, Urogenital Distress Inventory; SD,
standard deviation; IQR, interquartile range; IUT, invasive urodynamic testing
(intervention) arm; no IUT, no invasive urodynamic testing (control) arm
Table 6 Total numbers necessary in definitive trial when analysis
compares mean changes in ICIQ-FLUTS total score over six months
Difference to be detected
2 3 4
Number of RESPONSES to primary outcome 516 230 130
Number of RECRUITED patients 922 410 232
Number of eligible women APPROACHED 1182 526 298
Number of women SCREENED for eligibility 3194 1422 806
ICIQ-FLUTS, International Consultation on Incontinence modular questionnaires
- Female Lower Urinary Tract Symptoms questionnaire
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however, a small number who thought that participation
in the study automatically meant they would avoid the
invasive tests.
DID YOU THINK THERE WAS A POSSIBILITY
THAT YOU MIGHT HAVE THE INVASIVE TESTS?
Erm…no I think the registrar said to me if I signed up
for the study I wouldn’t have them. (Participant 08)
Experiences of study participation
The first set of questionnaires participants were asked to
complete at baseline was generally described as simple
to fill in, easy to understand, and straightforward.
HOW DID YOU FIND THE QUESTIONNAIRES YOU
WERE ASKED TO COMPLETE AT THE BEGINNING?
Simple.
WERE THEY TIME CONSUMING AT ALL?
No not particularly. (Participant 01)
A few minor issues were raised: there wasn’t always a
box to tick that was applicable to them, some questions
were hard to answer (for example, when asked to work
out costs or where judgement was called for), and some
thought the questions were a little repetitive.
Sometimes there wasn't, you know how there were tick
boxes kind of thing, it…none of those were really the
answer that I wanted to give. (Participant 11)
There were also some comments on the practical chal-
lenges associated with measuring urine output for the
bladder diary.
I found it more difficult to collect the urine. You know
to get down to it and have clear, clear days to get on
with it. (Participant 18)
The second set of questionnaires sent out 6 months
after treatment were similarly felt to be relatively simple
to complete. However, given that many had had successful
treatment and now had few, if any, symptoms to report,
the questions did not always seem relevant. Indeed, one
participant reported having called the study office to check
she had been sent the right questionnaires, and others
were a little concerned it might appear that they had not
completed the questionnaires at all because so much was
not now applicable to them.
I actually sent it back with absolutely nothing on it at
all because it said ‘have you been to visit the doctor in
6 months’, and I hadn't and it said go to the next section,
and go to the next section and so by the end of it, there
was nothing on it and I sent it back completely blank
and I thought they will think I have not bothered filling
this in. (Participant 14)
While some actually found completing the 6-month
questionnaires quite enjoyable (as it underlined for them
how successful the treatment had been), others reported
finding them burdensome and irrelevant now they had
few or no symptoms to report.
Not relevant at all, not to me anyway. Yes, because I
mean the problem was solved then so, why harp on
about how many pads am I wearing now because I don't
wear them, simple as that, nothing. (Participant 09)
This seemed particularly to apply to the bladder
diaries.
It did want another bladder diary I think afterwards
and I have not completed the bladder diary because I
just didn't get round to it to be honest with you. I had
it in my bag to take to work with me and I just didn't
get round to doing it. (Participant 21)
Discussion
The findings and implications of this pilot are considered
in subsequent sections across a number of aspects of the
trial design [60]. In terms of the ADePT approach, the
problems identified related to aspects of trial process and
were therefore classified as Type A - issues likely to be a
problem only for a trial, but not in the real world [45].
Overall, the logistics and study procedures were seen
to be adequate and functional in most areas, and import-
ant insights were gained to inform the design and effi-
cient conduct of any future definitive trial. These include
the following: allowing a realistic time frame for regula-
tory approval and site start-up, clarity over inclusion/ex-
clusions, modifying screening processes, reduction in
secondary outcomes, modification to patient question-
naire booklets and bladder diaries, and employing a
range of strategies to retain trial centre engagement (for
example, website, newsletters, recruitment updates).
Eligibility, recruitment, consent and randomisation
We found that 37 % of the women screened were
deemed eligible for the trial. This figure varied between
centres, as did the declared reasons for ineligibility.
More than half of all the women screened were from
one centre. It is likely that the assiduousness of re-
cruiters and interpretation of eligibility criteria differed
between centres. Running screening training exercises
might be considered for a future definitive trial to ensure
similar screening standards and practices and an ‘as-
sumed eligibility’ approach in all centres. This should be
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feasible, for example, by ‘clustering’ centres geographically
and carrying out training exercises alongside site setup
visits; we do not, however, have evidence of the effective-
ness of this proposed solution.
Recruitment was initially slow and was more success-
ful in some centres than others. Recruitment was ini-
tially delayed by the fact that ethical and regulatory
requirements for a multi-centre study took longer than
expected, and any definitive trial should determine and
allow a realistic timeframe for this.
Once approvals were in place, it was necessary to ex-
pand the number of planned centres and clinicians
within centres to meet recruitment targets; this high-
lights the need for rigorous and realistic site feasibility
assessments prior to site selection and setting and on-
going monitoring of individual site targets.
Whilst there is little high-quality evidence to support
their use [64], a range of strategies was used to retain
trial centre engagement such as regular recruitment up-
dates and newsletters. However we were eventually able
to recruit patients from all our study centres in sufficient
numbers to confirm that recruitment was feasible.
Of those women who screened positive, 78 %
consented to enter the trial. Data from the patient inter-
views suggested that most women reacted positively to
the invitation to take part, and found the information
provided about the study to be clear. There was no clear
preference for either the shorter or longer version of the
patient information sheet. The principle of random allo-
cation to one of two trial arms was generally well under-
stood by participants. The randomisation procedure led
to similar sized groups that were well balanced on base-
line variables.
Compliance with and acceptability of intervention
Most patients received the ‘IUT’ (91 %) or ‘no IUT’ group
tests (99 %) to which they were allocated. However, two
patients withdrew from the trial because they were un-
happy to be randomised to the ‘IUT’ arm, one failed to at-
tend the appointment for IUT, and four other patients in
the IUT arm did not undergo invasive tests for unspecified
reasons.
Outcome assessment, selection of most appropriate
outcomes and participant retention
Completion rates were relatively high for all question-
naires, and they had a similar rate and spread of missing
items. Rates of loss to follow-up after treatment were
significant, however, and whilst 75 % of women had ei-
ther face-to-face or telephone follow-up (typically at two
to three months) after surgical treatment, only 56 % (63 %
of those circulated) returned follow-up questionnaires
at 6 months.
It is recognised that the completion of question-
naires can be burdensome for participants [65], and
this may be particularly the case for those with few
or no symptoms. We found some evidence in the pa-
tient interview study to suggest that women were less
likely to return questionnaires if they were satisfied
with the results of their treatment, which may ac-
count for the number of blank questionnaires
returned at six months.
In any future definitive trial it would be necessary
to ensure a higher questionnaire response rate. The
UDI was the fourth instrument in a booklet of six
questionnaires in total, and had a slightly lower com-
pletion rate at both baseline and 6 months. The ques-
tions in ICIQ-UI SF overlap considerably with those
in the longer ICIQ-FLUTS and so we recommend
omitting both UDI and ICIQ-UI SF from any defini-
tive trial to reduce respondent burden. We anticipate
that this may improve completion of the remaining
items. Greater emphasis needs to be placed on the
importance of returning a completed questionnaire
even in the absence of any remaining symptoms. Al-
ternative modes of completion for follow-up question-
naires (for example, telephone or web based) and
providing incentives to return questionnaires are fur-
ther evidence-based strategies that might enhance re-
tention rates for data collection [66, 67].
Bladder diary data and pad test use were poorly com-
pleted in our pilot. This may be because many of the
women would have completed similar diaries or fre-
quency/volume charts earlier in their continence assess-
ment, because it may be seen as rather more intrusive
than simple questionnaire responses, or because it is pos-
sible that the diary design resulted in inconsistent comple-
tion of pad-use data. The trial recruitment process
enrolled only women with SUI or stress-predominant
MUI, the diary data did not show any evidence of abnor-
mal urinary frequency or nocturia, and there appeared to
be no change at 6 months in either arm (other than in
pad-use). In order to increase the completion rate of in-
continence episode data, diary data and pad use might be
omitted or modified in any definitive trial.
Alternative modes of completion for follow-up ques-
tionnaires, such as by telephone or online, and the
provision of modest incentives to return the question-
naires [66, 67] are further evidence-based strategies that
might enhance retention rates for data collection. A fur-
ther possibility is to link questionnaire completion at
follow-up to the face-to-face clinic review, thereby
allowing a check by a research nurse or trial coordinator
of item completion before patients leave the clinic area;
however, this would have required a change to the
current practice of some units, and risked the pragmatic
nature of the trial.
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Sample size calculation for a definitive trial
Sample size estimates were calculated for target differ-
ences of 2, 3, and 4 units in ICIQ-FLUTS, using the
standard deviation of the primary outcome data from
the pilot trial. However, a monograph on ways of speci-
fying a target difference for a trial recommended that es-
timates of sample size should be determined by more
than one approach [68]. In any definitive trial, the fol-
lowing data sources might be amongst those considered:
1. Clinician opinion
2. Data from the external pilot trial
3. A value of information study (not included here, but
forming part of a separate report) [42].
A survey update in June 2013 of consultant members
of BSUG and BAUS-SFNUU sought their views on what
constitutes a minimum clinically significant target differ-
ence in ICIQ-FLUTS combined score. However, the
ICIQ-FLUTS scale has not been used in many published
studies to date, and, perhaps because it is therefore not
familiar, only 50 % of consultants responding expressed
an opinion. There was no evidence of a common opin-
ion: given a choice of seven ranges of the scale to define
a clinically important difference (from 1–4 to >24), all
these ranges were chosen by at least one clinician, with
the modal range being 9 to 12. In separate discussions,
members of the study team did not find it easy to choose
a target difference based on the limited use of the scale
so far. The current lack of data from published trials
using ICIQ-FLUTS, and therefore evidence on which to
base expert judgement, casts some doubt of the useful-
ness of a survey of experts in this situation.
When the pilot trial results became available, it was
apparent that the distribution of the ICIQ-FLUTS total
score at 6 months and the difference between the scores
at baseline and 6 months typically had low values. The
mean score (SD) at 6 months in the ‘no-IUT’ arm was
6.9 (5.0) and the mean change between baseline and 6
months was 9.3 (7.3). It was apparent, therefore, that it
is not realistic to expect differences in mean outcomes
between trial arms in the order of 9 to 12 units, as pro-
posed in clinician survey responses. Based upon the trial
results, the study team decided that differences of 2, 3 or
4 units would be realistic differences that might be
achieved in any comparison of an intervention for
women eligible for a future trial.
Given the observed standard deviations, these target dif-
ferences of 2, 3 or 4 units are equivalent to standardised ef-
fect sizes of 0.29, 0.43 and 0.57 when comparing mean
changes in score over 6 months. In contrast, a difference of
9 to 12 units would equate to a standardised effect size of
1.5 to 2, which is a very large difference; many trials are
planned on a standardised effect size of around 0.5. Cohen
has suggested that standardised differences of 0.2, 0.5 and
0.8 correspond to ‘small’, ’medium’ and ‘large’ effect sizes
[20].
If a study is planned on the basis of a ‘realistic’ value
for the target difference, then consideration has to be
made of whether this is also a ‘clinically important’ dif-
ference. If it is clear that this is not a ‘clinically import-
ant’ difference, then there are real doubts as to whether
the trial should take place. It was felt that a difference of
around three units would also be of clinical interest
since a decrease of this level would equate to complete
recovery for one of the symptoms assessed in the ICIQ-
FLUTS score.
In this pilot trial, we identified 771 women for screen-
ing from seven centres over the course of 114 centre
screening months (approximately 6.8 women/centre/
screening month). Extrapolation of these figures would
require 120 to 480 centre screening months to achieve
the recruitment of 200 to 900 women. This would mean
four to 20 centres recruiting for approximately 30
months or six to 30 centres recruiting over 18 months.
Conclusions
Overall, the pilot trial can be considered a success, and a
definitive trial is feasible and remains necessary. The
study procedures were seen to be adequate and func-
tional in most areas, and important insights were gained
to inform the design and efficient conduct of a future
definitive trial.
Lessons were learned in how to manage the time
needed to bring multiple centres online through the UK
regulatory process; likely variation in recruitment from
the multiple centres has been observed and the import-
ance of standardised and assiduous screening recog-
nised; and effective methods of communication to keep
staff engaged through the lifetime of a long study have
been rehearsed and refined. Refinements in the data col-
lection process that will improve the quantity and qual-
ity of the data for a definitive trial have been identified.
Although recruitment was initially slow, patients were re-
cruited from all study centres in sufficient numbers to con-
firm that recruitment is feasible and that women are happy
to engage with the study objectives and be randomised.
Participants were very positive about the study, and in par-
ticular allayed fears over whether research to ‘test a test’
would be seen as important. The interviews also offered
suggestions as to how the experience of participation could
be improved and data collection maximised.
Based upon a range of target differences derived from the
observed clinical outcomes in this pilot RCT, any definitive
trial may need to recruit between 200 and 900 women.
With recruitment rates also based upon the pilot RCT, this
would mean four to 20 centres recruiting for approximately
30 months or six to 30 centres recruiting over 18 months.
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